Advertisement

Biotherapy

, Volume 5, Issue 4, pp 275–280 | Cite as

Interferon-α, interferon-γ and sizofiran in the adjuvant therapy in ovarian cancer — a preliminary trial

  • Jui-Tung Chen
  • Katsuhiko Hasumi
  • Kazumasa Masubuchi
Article

Abstract

The study included 24 cases of negative second-look laparotomy (SLL) after operation on ovarian cancer. 12 cases were treated with sizofiran and recombinant interferon-γ before and after SLL and then with human lymphoblastoid interferon-α. The remaining 12 cases (controls) were followed up without any drug therapy after SLL.

There were no recurrences in the treated group, but in 3 cases of the control group.

Also significant difference in survival was noted in the treated group.

Key words

human lymphoblastoid interferon-α ovarian cancer recombinant interferon-γ recurrence second-look laparotomy sizofiran 

Abbreviations

SLL

Second-look laparotomy

rIFN-γ

recombinant interferon-γ

HLBI

human lymphoblastoid interferon-α

Mϕ

macrophage

CDDP

cisplatin

ADM

adriamycin

CPM

cyclophosphamide

i.m.

intramuscular

i.p.

intraperitoneal

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Berek JS, Hacker NF, Lagasse LD, Poth T. Resnick B, Nieberg RK. Second-look laparotomy in stage III epitherial ovarian cancer: Clinical variables associated with disease status. Obstet Gynecol 1984; 64: 207–12.Google Scholar
  2. 2.
    Cain JM, Saigo BE, Pierce VK et al. A review of second-look laparotomy for ovarian cancer. Gynecol Oncol 1986; 23: 14–25.Google Scholar
  3. 3.
    Gershenson DM, Copeland LJ, Wharton JT et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985; 55: 1129–35.Google Scholar
  4. 4.
    Podratz KC, Malkasian GD Jr, Wieand HS, et al. Recurrent disease after negative second-look laparotomy in stage III and IV ovarian carcinoma. Gynecol Oncol 1988; 29: 274–82.Google Scholar
  5. 5.
    Raju KS, McKinna JA, Baker GM, Wiltshaw E, Jons JM. Second-look operations in the planned management of advanced ovarian carcinoma. Am. J Obstet Gynecol 1982; 144: 650–4.Google Scholar
  6. 6.
    Matsuo T, Arika T, Mitani M et al. Pharmacological and toxicological studies of a new antitumor polysaccharide, Shizophyllan. Arzneim-Forsch 1982; 32: 647–56.Google Scholar
  7. 7.
    Tsuchiya Y, Igarashi M, Inoue M et al. Cytokine-related immunomodulating activities of an anti-tumor glucan. J Pharmacobio-Dyn 1989; 12: 616–25.Google Scholar
  8. 8.
    Billard C, Diez RA, Ferbus D et al. Similar biological effects of different low dose of interferon alpha in cancer patients. Br J Cancer 1987; 55: 677–9.Google Scholar
  9. 9.
    Marshall ME, Simpson W, Butler K, Fried A, Fer M. Treatment of renal cell carcinoma with daily low-dose alpha-interferon. J Biol Response Mod 1989; 8: 453–61.Google Scholar
  10. 10.
    Wadler S, Goldman M, Lyver A, Wiernik PH. Phase I trial of 5-fluorouracil and recombinantα2a-interferon in patients with advanced colorectal carcinoma. Cancer Res 1990; 50: 2056–9.Google Scholar
  11. 11.
    Chen JT, Teshima H, Shimizu Y, Hasumi K, Masubuchi K. Morphological change in human peritoneal macrophages treated with sizofiran or recombinant interferon-γ. Igaku No Ayumi 1989; 150: 505–6.Google Scholar
  12. 12.
    Lippman SM, Alberts DS, Slymen DJ, et al. Second-look laparotomy in epitherial ovarian carcinoma. Prognostic factors associated with survival duration. Cancer 1988; 61: 2571–7.Google Scholar
  13. 13.
    Lund B, Williamson P. Prognostic factors for outcome of survival after second-look laparotomy in patients with advanced ovarian carcinoma. Obstet Gynecol 1990; 76: 617–22.Google Scholar
  14. 14.
    Chambers SK, Chambers JT, Kohorn EI, Lawrence R, Schwartz PE. Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 1988; 72: 404–8.Google Scholar
  15. 15.
    Creasman WT, Gall S, Bindy BN, Beechman J, Mortel R, Homesley HD. Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (A gynecologic oncology group study). Gynecol Oncol 1989; 35: 378–82.Google Scholar
  16. 16.
    Podratz KC, Schray MF, Wieand HS, et al. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988; 31: 9–21.Google Scholar
  17. 17.
    Schwartz PE, Smith JP. Second-look operations in ovarian cancer. Am J Obstet Gynecol 1980; 138: 1124–30.Google Scholar
  18. 18.
    Simpson HL, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 1976; 60: 1749–60.Google Scholar
  19. 19.
    Podoratz KC, Malkasian GD, Hilton JF, Harris EA, Gaffey TA. Second-look laparotomy in ovarian cancer: Evaluation of pathologic variables. Am J Obstet Gynecol 1985; 152: 230–8.Google Scholar
  20. 20.
    Barnhill DR, Hoskins WJ, Heller PB, Park RC. The second-look surgical reassessment for epithelial ovarian carcinoma. Gynecol Oncol 1984; 19: 148–54.Google Scholar
  21. 21.
    Ghatage P, Krepart GV, Lotocki R. Factor analysis of false-negative second-look laparotomy. Gynecol Oncol 1990; 36: 172–5.Google Scholar
  22. 22.
    Dauplat J, Ferriere JP, Gorbinet M et al. Second-look laparotomy in managing epitherial ovarian carcinoma. Cancer 1986; 57: 1627–31.Google Scholar
  23. 23.
    Ochiai K. Reassessment of second look operation (SLO) in the treatment of ovarian cancer patients. Jpn J Cancer Chemother 1989; 16 (PART-II): 1303–9.Google Scholar
  24. 24.
    Freedman RS. Recent immunologic advances affecting the management of ovarian cancer. Clin Obstet Gynecol 1985; 28: 853–71.Google Scholar
  25. 25.
    Chen JT, Teshima H, Shimizu Y, Hasumi K, Masubuchi K. Effect of sizofiran or recommbinant interferon gamma on the activation of human peritoneal macrophage function; An approach for the prophylaxis of intraperitoneal recurrence of ovarian cancer. Acta Obst Gynaec Jpn 1990; 42: 179–84.Google Scholar
  26. 26.
    Chen JT, Teshima H, Shimizu Y, Hasumi K, Masubuchi K, Suzuki M. Sizofiran and recombinant interferon gamma stimulate peritoneal macrophages obtained from patients with gynecologic malignacies. - Increased secretion of tumor necrosis factor, IL-1 and interferon gamma. Jpn J. Cancer Chemother 1990; 17: 1365–69.Google Scholar
  27. 27.
    Chen JT, Hasumi K, Masubuchi K. Maintenance of the activation of peritoneal macrophage in patients with ovarian cancer by the repeat dosing of sizofiran and recombinant interferon-γ in combination. Biotherapy 1992; 5: 137–43.Google Scholar
  28. 28.
    Salmon SE, Durie BG, Young L, Liu RM, Trown PW, Stebbing N. Effects of cloned human leukocyte interferons in the human stem cell assay. J. Clin Oncol 1983; 1: 217–25.Google Scholar
  29. 29.
    Welander CE. Interferon in the treatment of ovarian cancer. Semin Oncol 1988; 15: 26–9.Google Scholar
  30. 30.
    Berek JS, Hacker NF, Lichtenstein A, et al. Intraperitoneal recombinant alpha-interferon for ‘salvage’ immunotherapy in stage III epitherial ovarian cancer. A gynecologic Oncology Group Study. Cancer Res 1985; 45: 4447–53.Google Scholar
  31. 31.
    Hacker NF, Lawton FG, Astbury LD, Penny R. Intraperitoneal interferon-alpha-2b for patients with a macroscopically negative second-look laparotomy. A preliminary report. In: Sharp F, Mason WP, Leake RE, eds: Ovarian Cancer: Biological and Therapeutic Challenges. London: Chapman & Hall Medical, 1990: 365–9.Google Scholar
  32. 32.
    Willemse PHB, De Vries EGE, Mulder NH, Aalders JG, Bouma J, Sleijfer DTH. Intraperitoneal human recombinant interferon alpha -2b in minimal residual ovarian cancer. Eur J Cancer 1990; 26: 353–8.Google Scholar
  33. 33.
    Kirkwood JM, Harris JE, Vera R et al. A randomized study of low and high doses of leukocyteα-interferon in metastatic renal cell carcinoma. The American Cancer Society Collaborative trial. Cancer Res 1985; 45: 863–71.Google Scholar
  34. 34.
    Johnson HM, Smith BG, Baron S. Inhibition of the primary in vitro antibody response by interferon preparations. J Immunol 1975; 114: 403–9.Google Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Jui-Tung Chen
    • 1
  • Katsuhiko Hasumi
    • 1
  • Kazumasa Masubuchi
    • 1
  1. 1.Department of GynecologyCancer Institute HospitalToshima-ku TokyoJapan

Personalised recommendations